Abstract
After much initial debate for and against the role of amyloid in Alzheimers disease (AD), mutations on the amyloid precursor protein (APP) and processing pathways that increase levels of the amyloid b peptide of 42 residues (Aβ42) have established that faulty function or processing of these proteins are responsible for AD pathogenesis. Given the neurotoxicity of aggregates of Ab42, the central role of this peptide in AD pathogenesis is self evident. In this article, I summarize the major pieces of evidence adduced to support the amyloid cascade hypothesis and point out their limitations
Keywords: APP mutations, neurodegenerative disease, oxidative stress, apolipoprotein, presenilin
Current Alzheimer Research
Title: Has the Amyloid Cascade Hypothesis for Alzheimers Disease been Proved?
Volume: 3 Issue: 1
Author(s): John Hardy
Affiliation:
Keywords: APP mutations, neurodegenerative disease, oxidative stress, apolipoprotein, presenilin
Abstract: After much initial debate for and against the role of amyloid in Alzheimers disease (AD), mutations on the amyloid precursor protein (APP) and processing pathways that increase levels of the amyloid b peptide of 42 residues (Aβ42) have established that faulty function or processing of these proteins are responsible for AD pathogenesis. Given the neurotoxicity of aggregates of Ab42, the central role of this peptide in AD pathogenesis is self evident. In this article, I summarize the major pieces of evidence adduced to support the amyloid cascade hypothesis and point out their limitations
Export Options
About this article
Cite this article as:
Hardy John, Has the Amyloid Cascade Hypothesis for Alzheimers Disease been Proved?, Current Alzheimer Research 2006; 3 (1) . https://dx.doi.org/10.2174/156720506775697098
DOI https://dx.doi.org/10.2174/156720506775697098 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism The Role of Fatty Acids in the Regulation of Cerebral Vascular Function and Neuroprotection in Ischemia
CNS & Neurological Disorders - Drug Targets Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Defining Dystonic Tremor
Current Neuropharmacology Takotsubo Cardiomyopathy
Current Pharmaceutical Design An Overview on Inventions Related to Ginger Processing and Products for food and Pharmaceutical Applications
Recent Patents on Food, Nutrition & Agriculture The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Editorial (Thematic Issue: Neurology and Genetics: How Molecular Biology is Changing the Neurological Thoughts?)
Current Molecular Medicine Estimating Alzheimer’s Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia
Current Alzheimer Research Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research The Ambidextrous Cyclooxygenase: An Enduring Target
Inflammation & Allergy - Drug Targets (Discontinued) Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
Current Neuropharmacology Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients
Current Alzheimer Research Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Age-Related Sleep Changes and its Implication in Neurodegenerative Diseases
Current Aging Science Inaccuracy in Clinical Trials: Effects and Methods to Control Inaccuracy
Current Alzheimer Research Alzheimers Disease and Immunotherapy
Current Alzheimer Research IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism <i>In Vivo/Ex Vivo</i> EPR Investigation of the Brain Redox Status and Blood-Brain Barrier Integrity in the 5xFAD Mouse Model of Alzheimer's Disease
Current Alzheimer Research